Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28223233)

  • 1. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.
    Neuzillet C; Rousseau B; Kocher H; Bourget P; Tournigand C
    Pharmacol Ther; 2017 Jun; 174():145-172. PubMed ID: 28223233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.
    Neuzillet C; de Mestier L; Rousseau B; Mir O; Hebbar M; Kocher HM; Ruszniewski P; Tournigand C
    Pharmacol Ther; 2018 Jan; 181():49-75. PubMed ID: 28723416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.
    El Dika I; Ilson DH
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1085-1092. PubMed ID: 30092682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
    Cervera P; Fléjou JF
    Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
    Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors to targeted treatment in gastrointestinal carcinomas.
    Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
    Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality.
    Kourie HR; Tabchi S; Ghosn M
    World J Gastroenterol; 2017 May; 23(17):3017-3021. PubMed ID: 28533658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting HER 2 and angiogenesis in gastric cancer.
    Jomrich G; Schoppmann SF
    Expert Rev Anticancer Ther; 2016; 16(1):111-22. PubMed ID: 26567753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies in gastrointestinal cancers.
    Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
    Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
    Tímár J; Láng I
    Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New advances in targeted therapies for squamous cell carcinoma of the head and neck.
    Machiels JP; Schmitz S
    Anticancer Drugs; 2011 Aug; 22(7):626-33. PubMed ID: 21048493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors in the Treatment of Gastrointestinal Malignancies: A Review of Current and Future Therapies.
    Hsu A; Mendelson L; Almhanna K
    R I Med J (2013); 2020 Apr; 103(3):33-37. PubMed ID: 32236159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
    Chen C; Di Bartolomeo M; Corallo S; Strickler JH; Goyal L
    Am Soc Clin Oncol Educ Book; 2020 May; 40():161-173. PubMed ID: 32421451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
    Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
    Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aquaporins: Their role in gastrointestinal malignancies.
    Nagaraju GP; Basha R; Rajitha B; Alese OB; Alam A; Pattnaik S; El-Rayes B
    Cancer Lett; 2016 Apr; 373(1):12-18. PubMed ID: 26780474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.